bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 145.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: 2813.87%
• EPS Growth: 5.64%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 78
• Industry: Medical Diagnostics & Screening
• EPS (TTM): -0.80
• Shares Outstanding: 15,584,635
• 10 Day Avg. Volume: 273,880
• 30 Day Avg. Volume: 145,011
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.59
• Price to Cash Flow (P/CF): -0.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 1566.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

bioAffinity Technologies, Inc. faces significant challenges, primarily in profitability, cash flow management, and technical indicators, which weigh heavily on its stock score. However, promising revenue growth and positive corporate events provide some optimism for future potential. The overall stock score reflects these mixed signals, indicating a cautious outlook requiring close monitoring of financial improvements and strategic execution.

Positive Factors

Market Expansion

The number of physician offices ordering CyPath Lung was roughly 140, up from ~100 at the end of 2Q24, indicating growth potential.

Product Development

BIAF is focused on changing the paradigm for the early detection of cancers, and its initial product, CyPath Lung, could become the standard-of-care.

Negative Factors

Financial Performance

BIAF reported 3Q24 results with revenue slightly below our estimate and a slightly wider GAAP loss per share.

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company Description

bioAffinity Technologies, Inc. (BIAF) is a biotechnology company focused on developing non-invasive diagnostics and targeted therapies for diseases of the lung. The company operates within the healthcare sector, specifically in the areas of oncology and respiratory diseases. Its core product includes CyPath Lung, a diagnostic test intended to detect early-stage lung cancer by analyzing samples from the lower respiratory tract.

How the Company Makes Money

bioAffinity Technologies, Inc. makes money primarily through the commercialization of its diagnostic products, such as CyPath Lung. The company earns revenue by selling these diagnostic tests to healthcare providers, hospitals, and laboratories. Additionally, bioAffinity may engage in partnerships with other biotechnology firms and research institutions to further develop and market its technologies, potentially generating additional revenue through licensing agreements, joint ventures, or research grants.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary

bioAffinity Technologies, Inc. demonstrates significant revenue growth but struggles with profitability, high cost pressures, and negative cash flows. The balance sheet shows improvement with positive equity, although high leverage is concerning. Overall, the company is in a growth phase but must address cash flow and debt challenges.

Income Statement

The company shows a significant increase in revenue from $2.5M in 2023 to $9.4M in TTM, indicating substantial revenue growth. However, profitability remains a challenge with negative net income and low margins, as evidenced by a negative net profit margin and EBIT margin. The gross profit margin is relatively low at 31.8% in TTM, reflecting high cost pressures.

Balance Sheet

The company has improved its equity position from negative $15.8M in 2021 to positive $3.1M in TTM, which is a positive sign. However, the debt-to-equity ratio remains concerning at 0.55 in TTM, indicating high leverage. The equity ratio is 47.6% in TTM, showing a moderate reliance on equity financing.

Cash Flow

The cash flow situation is challenging with negative operating and free cash flows, though there was a significant increase in financing cash flows in TTM. The free cash flow to net income ratio is negative, which raises concerns about the sustainability of operations. The operating cash flow to net income ratio also indicates inefficiencies in cash generation.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
9.37M	2.53M	4.80K	0.00	0.00	0.00
	Gross Profit
2.98M	791.62K	4.34K	-4.82K	-22.24K	-40.28K
	EBIT
-8.35M	-7.97M	-4.01M	-2.21M	-2.60M	-3.09M
	EBITDA
-7.74M	-7.63M	-5.61M	-2.20M	-6.86M	-3.05M
	Net Income Common Stockholders
-8.45M	-7.94M	-8.15M	-6.33M	-7.27M	-3.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
83.11K	2.82M	11.41M	1.36M	83.11K	578.48K
	Total Assets
145.60K	8.22M	12.18M	1.45M	145.60K	658.81K
	Total Debt
10.01M	1.58M	251.75K	11.36M	10.01M	4.01M
	Net Debt
9.92M	-1.24M	-11.16M	10.00M	9.92M	3.43M
	Total Liabilities
11.17M	3.37M	1.14M	17.24M	15.22M	4.69M
	Stockholders Equity
-11.03M	4.86M	11.04M	-15.79M	-15.07M	-4.04M
Cash Flow		Free Cash Flow
-7.27M	-6.06M	-4.29M	-2.05M	-2.21M	-2.50M
	Operating Cash Flow
-7.20M	-6.04M	-4.07M	-2.05M	-2.21M	-2.49M
	Investing Cash Flow
-65.64K	-2.21M	-219.99K	0.00	-2.89K	-11.40K
	Financing Cash Flow
3.52M	-344.98K	14.34M	3.33M	1.72M	2.33M

bioAffinity Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.72, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 24.64 is Positive, neither overbought nor oversold. The STOCH value of 23.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.

bioAffinity Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRA	68 Neutral	$18.93B	―	-19.42%	―	56.75%	59.77%
CDNA	68 Neutral	$1.02B	18.09	19.46%	―	19.07%	―
EXAS	53 Neutral	$8.52B	―	-37.09%	―	10.37%	-389.98%
GH	53 Neutral	$5.26B	―	-4584.47%	―	31.04%	16.91%
ILMN	49 Neutral	$13.39B	―	-30.11%	―	-2.93%	-4.69%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
BIAF	42 Neutral		―	-167.00%	―	2813.87%	5.64%

bioAffinity Technologies, Inc. Corporate Events

bioAffinity Technologies Adjusts CEO Compensation Package

On January 10, 2025, bioAffinity Technologies, Inc. announced that its Compensation Committee approved an amendment to increase the annual base salary of CEO Maria Zannes to $300,000, effective retroactively from November 1, 2024. This adjustment to the CEO’s compensation package reflects ongoing strategic decisions within the company that could have implications for its financial management and stakeholder relations.

bioAffinity Technologies Boosts Sales with CyPath Lung

bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test.